New Drug Reverses Severe Fatty Liver Disease by Restoring Gut Health in Animal Models

An experimental drug, DT-109, developed at Michigan Medicine, has successfully reversed severe fatty liver disease (MASH) in animal models. The drug works by targeting the gut, reducing harmful bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver, offering a promising new strategy for treating this difficult-to-manage disease.